In particular, aromatase inhibitors (AIs), which lower circulating estrogens limiting their proliferative effect on breast cancer cells, are now the gold standard for the hormonal therapy of postmenopausal women with breast cancer [3]. Here, CYP19A1 is linked to breast cancer.